USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Takeda Pharmaceutical Company Limited

USPTO PatentsView assignee record - 668 granted patents across 61 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

668

Total patents granted

CPC technology areas

13.9

Avg claims per patent

+27%

5-year filing velocity

The verdict

Takeda holds 668 US patents across 61 technology areas, rank #675 of 50,000 tracked assignees.

#675
of 50,000 US assignees by volume: Top 1%
by Innovation Score (64.7/100): 13.9
avg claims per patent: +27%
filing velocity, last 5 yrs

Portfolio overview

Takeda Pharmaceutical Company Limited has been granted 668 US utility patents between 2015 and 2025, placing Takeda Pharmaceutical Company Limited at rank #675 across all assignees tracked by PlainPatent. This portfolio spans 61 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.9 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Takeda Pharmaceutical Company Limited is one of the broader-portfolio assignees in the PatentsView dataset. By volume, Takeda sits between BAE Systems Plc (669 patents, rank #671) and Datang Mobile Communications Equipment Co., Ltd. (661 patents, rank #679) - the closest US assignees by grant volume. The composite Innovation Score of 64.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 374 grants, compared with 294 in the 2015–2019 window, a +27% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Takeda Pharmaceutical Company Limited's 13.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 61 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Takeda Pharmaceutical Company Limited against peers pursuing similar technology classes.

BAE Systems

669
Kuraray

669
King Abdullah Uni…

669
Socionext

668
Takeda Pharmaceut… ◀

668
thyssenkrupp

665
Groupon

664
Boehringer Ingelh…

662
Datang Mobile Com…

661

What this shows Takeda holds 668 patents at rank #675, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Takeda

By rank, the assignees closest to #675 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Takeda's primary technology class.

Takeda's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

65 Top 1% higher than 99% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Takeda Pharmaceutical Company Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	67	10.0%
2016	62	9.3%
2017	61	9.1%
2018	47	7.0%
2019	57	8.5%
2020	46	6.9%
2021	52	7.8%
2022	60	9.0%
2023	70	10.5%
2024	77	11.5%
2025	69	10.3%

Which technologies does Takeda Pharmaceutical Company Limited patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 535

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 407

C07D - HETEROCYCLIC COMPOUNDS 364

C07K - PEPTIDES 116

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 87

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 41

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 39

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 38

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 34

C12Y - ENZYMES 31

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 17

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 16

B01J - CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS 15

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 14

A61J - CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE 10

Top 15 of 61 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#675

Across all tracked assignees

Innovation Score

64.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Takeda Pharmaceutical Company Limited hold?

Takeda Pharmaceutical Company Limited holds 668 US granted patents filed between 2015 and 2025, spanning 61 technology areas.

What is Takeda Pharmaceutical Company Limited's Innovation Score?

Takeda Pharmaceutical Company Limited has an Innovation Score of 64.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Takeda Pharmaceutical Company Limited focus on?

Takeda Pharmaceutical Company Limited's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 535 patents. The company has filed patents in 61 CPC subclasses total.

Is Takeda Pharmaceutical Company Limited's patent filing rate increasing or decreasing?

Takeda Pharmaceutical Company Limited's recent filing velocity is +27% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Takeda Pharmaceutical Company Limited's patents?

Takeda Pharmaceutical Company Limited's patents average 13.9 claims each. This falls within the standard range, providing solid legal coverage.

How is the Takeda Pharmaceutical Company Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Takeda's 668 grants land it in the top 1% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Takeda ranks #675 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.